Beximco Pharmaceuticals Limited has started exporting to Canada an ophthalmic product, Olopatadine, used in treating symptoms of eye allergies. The fast-growing manufacturer of generic pharmaceutical products made the announcement yesterday. Following the approval of Health Canada, the Olopatadine export kicked in – the first of any kind of pharmaceutical product in the North American country from Bangladesh. According to the IMS data, the current market size for Olopatadine eye drops including all strengths in Canada is $14 million. Beximco Pharma’s second prescription product for the Canadian market is currently under evaluation by Health Canada, with approval being expected by the first quarter of 2018.

Source: Dhaka Tribune September 18, 2017 10:30 UTC